Just as trans-splicing PTMs can be engineered to address the tau isoform imbalance in patients with frontotemporal dementia with parkinsonism linked to Chromosome 17, RNAi could be used to reprogram this balance by reducing the levels of exon 10+ splice variants. This evidence concerns the gene MAPT and Parkinson disease.